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In past decade, cephalosporins have developed significantly, and data regarding
novel cephalosporins (i.e., ceftobiprole, ceftaroline, ceftolozane/tazobactam,
ceftazidime/avibactam, and cefiderocol) within septic and bacteremic subjects are rising.
These compounds generally offer very promising in vitro microbiological susceptibility,
although the variability among gram-negative and -positive strains of different cohorts is
noticed in the literature. We require further pharmacological data to measure the best
dose in order to prevent sub-therapeutic drug levels in critically ill patients. These new
compounds in theory are the sparing solution in the Enterobacteriales infection group
for different antimicrobial classes such as aminoglycosides notably within endovascular
and GNB-bacteremias, as well as colistin and carbapenem-sparing strategies, favoring
good safety profile molecules. Moreover, new cephalosporins are the basis for the actual
indications to open up new and exciting prospects for serious infections in the future.
In future, patients will be addressed with the desirable approach to sepsis and serious
infections in terms of their clinical situation, inherent features of the host, the sensitivity
profile, and local epidemiology, for which evidence of the use of new cephalosporin in
the treatment of severe infections will fill the remaining gaps.
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INTRODUCTION
Sepsis has been defined as “one of the oldest and most elusive syndromes in medicine” (1). In
2017 Rudd et al. estimated, worldwide, 48.9 million cases of sepsis and 11.0 million deaths due
to sepsis (2). Sepsis complexity resides in a dysregulated host response to an infection and in
jeopardy to develop acute organ dysfunctionwith a high risk of in-hospital mortality rates estimated
between 25 and 30% (3). This syndrome requires urgent treatment; thus, an awareness of the
presenting characteristics of sepsis is highly important (4). In medicine, we must always look to
the past with an eye to the future. From this perspective, this paper evaluates and discusses the
available data on novel cephalosporins (i.e., ceftobiprole, ceftaroline, ceftolozane/tazobactam [C/T],
ceftazidime/avibactam [C/A], and cefiderocol) (5) in the antimicrobial management of sepsis and
severe infections to assess whether these new molecules can provide innovative answers to ancient
questions (6).
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CEPHALOSPORINS WITH A MAIN
ANTI-MRSA ACTIVITY
Ceftobiprole
Ceftobiprole medocaril is currently approved in Europe as an
extended-spectrum cephalosporin for adult community acquired
and nosocomial, non-ventilator-associated pneumonia (i.e., CAP
and HAP) (7, 8), and skin and soft tissue infection (SSTIs),
including diabetic foot infections (9, 10).
Clinical application and actual experiences with ceftobiprole
are limited but nevertheless promising for sepsis and
bloodstream infections (BSIs) (11, 12). A discreet proportion
of gram-positive sepsis was included in phase III trials for
CAP, HAP and SSTIs (7–10). Rello et al. (13) developed
two interesting grouped analyses—a test of cure (TOC) and
mortality—for ceftobiprole, vs. comparators (e.g., vancomycin,
linezolid, and ceftazidime) for Staphylococcus spp. BSIs through
the extrapolation of the clinical data directly from phase III
studies (7–10). In the TOC analysis, the clinical cure rate of the
ceftobiprole group (48.9 percent, 22/45 patients) was similar
to that of the comparators (44.0 percent, 22/50), specifically
the subgroups of coagulase-negative staphylococci (CoNS;
45.5 vs. 45.5%), methicillin-sensitive Staphylococcus aureus
(MSSA; 44.4 vs. 46.7%), and methicillin-resistant S. aureus
(MRSA; 55.6 vs. 22.2%) (12, 13). Furthermore, the 30-day
all-cause mortality in the ceftobiprole group was 8.9% (4/45)
vs. 16.0% (8/50) in the comparator group (12, 13). In the
ceftobiprole group, death rates were zero for MRSA bacteraemic
patients compared with 22.2 per cent in the comparator cohorts
(12, 13). Despite the interesting results, the conclusions drawn
by Rello et al. had been obtained from a sample of just 18
patients, without a complete analysis of all data in the entire
subgroup (13).
Ceftobiprole (alone or in combination) could therefore play
an important role in treating endovascular infections due to
its high bactericidal activity, favorable resistance profile, and
potential synergism with other antigram-positive molecules
(11–13). In a rat model of endocarditis, a subtherapeutic
dose of ceftobiprole plus vancomycin was as effective against
MRSA and vancomycin intermediate-resistant S. aureus
strains as ceftobiprole standard dose monotherapy (14, 15).
Theoretically, ceftobiprole used to treat endocarditis could
permit a nephrotoxic-sparing strategy, thus avoiding the
aminoglycoside and glycopeptide side effects and the need
for therapeutic drug monitoring. Ceftobiprole also plays a
vital role in penicillin-allergic subjects with severe gram-
positive infections (11–13). A daptomycin-based scheme,
complemented with an adjunct of ceftobiprole, also seems
promising in clinical applications within endocarditis
therapeutic management (16, 17). An ongoing non-inferiority
trial (double-blinded and randomized, https://clinicaltrials.
gov/ct2/show/NCT03138733) comparing standard dose
ceftobiprole and daptomycin (6 mg/kg/24 h) in adult patients
with S. aureus bacteraemia (including right-sided infective
endocarditis) will provide more information (18). One
potential concern surrounding ceftobiprole is determining
the adequate dosage for bacteraemia and endocarditis. The
prospect of accomplishing this target for MRSA strains
with the ongoing approved dose is >90% with MIC of 4
mg/L (19–21).
A higher exposure (100% T > MIC) is however associated
with strong bactericidal action and therefore is the preferred
goal for severe and high inoculum infections (19–21). With the
current dose the probability of receiving 100% > T > MIC for
MRSA strains will be lower, but this can be improved significantly
through the prolonged infusion (over 4 h) or ongoing infusion of
patients at higher doses (500 mg/6 h or 1 g/8–12 h) (19–21).
Little is known about CSF penetration for ceftobiprole,
which may still be a valuable option in primary meningitis
caused by Streptococcus pneumoniae (including penicillin-
and ceftriaxone-resistant strains) and secondary, post-surgical
meningitis requiring both gram-positive and susceptible gram-
negative coverage (11–13, 22). The antibacterial activity was
comparable to cefepime with β-lactamase-negative strains
of Escherichia coli, Klebsiella pneumoniae, and Haemofilus
influenzae in the animal model proposed by Stucki et al. (22).
Moreover, the same authors (22) discovered that ceftobiprole
reached about 16% of serum levels through inflamed meninges
compared to about 2% of serum levels through uninflamed
meninges in a rabbit meningitis model, similarly to cefepime
pharmacokinetic in CSF.
This fifth-generation cephalosporin has been approved for
official indications of CAP and HAP adults in 12 European
countries, Canada, and Switzerland (11). Moreover, ceftobiprole
blends excellent spectrum with beta-lactam safety for low
to moderate MDR HAP pathogenes in frail patients who
could be at great risk from adverse effects caused by
MRSA or anti-MRSA coverage, including oxazolidinones or
glycopeptides (6, 11, 12).
There are promising activities of this novel cephalosporins
on MRSA isolates, including Panton-Valentine Leukocidine
positive strains, whether or not it is a slight change
depending on the type of SCCmec, as shown in recent
findings concerning ceftobiprole isolates in Phase III
SSTI and pneumonia studies (23, 24). In severe adult
CAP, coinfection, or superinfection over viral pneumonia,
ceftobiprole can be a suitable option when the risk
for MRSA or susceptible P.aeruginosa coinfection is
high (6, 11, 12).
VAP still represents an area of uncertainty according to
clinical trial results (8) due to the inadequate sample size
and substantial baseline sample heterogeneous features (6).
Ceftobiprole data for BSIs in real life are limited, but promising,
despite the need for further pharmacokinetic data in special
populations such as patients with critical illness or elevated
creatinine clearance (25).
Ceftaroline
Ceftaroline is a fifth-generation cephalosporin with a peculiar
affinity to the penicillin binding protein (PBPs) 2a, an MRSA-
specific protein, with an excellent spectrum of activity on
common bacterial causes of CAP (26, 27) and SSTIs (28).
Ceftaroline has activity against a wide spectrum of gram-
positive bacteria including MSSA and MRSA, also including
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some resistant S. aureus strains (vancomycin intermediate,
heterogeneous vancomycin intermediate, vancomycin-resistant,
or daptomycin non-susceptible) and MDR S. pneumoniae
(29–31). Moreover, ceftaroline also exhibits activity against
a broad group of gram-negative, ESBL-negative, or AmpC-
producing Enterobacteriaceae (29–31). The US Food and Drug
Administration (FDA) approved a label expansion for the
treatment of S. aureus bacteraemia associated with SSTIs in
adults in 2015 and in the pediatric population in 2016 (32).
The literature regarding the bacteraemic cohorts of patients
treated with ceftaroline (alone or in combination) is growing
and has been mostly comprised of subjects with a diagnosis of
either persistent bacteraemia or MRSA bacteraemia that is not
susceptible to vancomycin or daptomycin (32–47). Persistent
bacteraemia (with or without a known focus of infections) is not
an uncommon finding, which may be associated with increased
mortality and morbidity, and refers to blood cultures that were
positive within the same infectious episode and on different
days (33, 34). Interesting observations on time to eradication of
MRSA in BSIs were extrapolated from a retrospective matched
case-control study by Paladino et al. (33): the ceftaroline cohort
reported a median time to eradication that was about half the
median time of the control group treated with vancomycin (4
vs. 8 days; interquartile range [IQR]: 3.0–7.5 days vs. 5.8–19.5
days; P = 0.02). The time to eradication was further reduced
to 2 days (IQR: 1–4 days) in Arshad et al.’s (34) multicenter
observational study of 211 patients (33). Clinical success in the
most representative studies has ranged from 60 to 88% (34–
39). Interestingly, Arshad et al. (34) reported a clinical cure
rate of 69.7% when ceftaroline was used as a monotherapy
and 64.9% when it was used in combination. Furthermore,
even a microbiological cure reported good results, between 70
and 100%, but these were variable depending on the time of
consideration (34). Mootz et al.’s (45) retrospective comparative
effectiveness study included adults hospitalized with sepsis who
received ceftaroline or daptomycin within 14 days of hospital
admission. Patients treated with ceftaroline were less likely to
experience readmission at 30 days (25 vs. 37%, P = 0.06), 60
days (27 vs. 44%, P = 0.008) and 90 days (28 vs. 46%, P =
0.01) compared to those treated with daptomycin (45). Moreover,
the ceftaroline group showed a lower in-hospital mortality rate
(7 vs. 12%, P = 0.4) at 30 days (3 vs. 9%, P = 0.1), 60 days
(6 vs. 12%, P = 0.2), and 90 days (7 vs. 15%, P = 0.1) vs. the
comparator (45).
Ceftaroline, a rapid BSI clearance beta-lactam, also serves as
an interesting solution to complicated endocarditis (46). This
is illustrated by the retrospective CAPTURE analysis involving
55 patients receiving ceftaroline treatment with gram-positive
endocarditis (47). The overall success rate in this study was
70.9% (47). In particular, ceftaroline therapies were extremely
effective as a first-line therapy (75.0%) as well as in patients
suffering from right-sided endocarditis (80.8%) and MRSA
(77.3%) (47).
Ceftaroline is currently used in the management of persistent
gram-positive bacteraemia (36) and, also due to the wide
spectrum of microbiological activity comprising gram-negative
organisms, may be a feasible choice for catheter-related
and -associated BSIs (12, 32). The bactericidal and time-
dependent activity of ceftaroline, as well as ceftobiprole,
could potentially be implemented in therapeutic schemes
for bacteraemia and endovascular infection to improve
the safety of kidney function, limiting glycopeptides and
the need for therapeutic monitoring, with consistent
advantages in centers with scarce laboratory resources
(11, 12, 32, 33). Ceftaroline could also be used in the
treatment of severe infections, including both primary (e.g.,
post-traumatic) and secondary (e.g., post-surgical) bacterial
meningitis, although few data are available for CSF drug
concentrations (48, 49).
Stucki et al. (48) estimated that 15% of the serum level
of CSF penetrated inflammatory meninges and about 3%
of non-inflamed meninges. Mermer et al. (49) found that
in an experimental meningitis model both ceftaroline and
vancomycin have similar antibacterial efficacy in treating
MRSA. Pani et al. (32) confirmed the use of ceftaroline as





C/T is a combination of the renowned β-lactamase inhibitor
tazobactam and an innovative anti-pseudomonal cephalosporin
(5, 50). The FDA and the EMA have approved C/T for
complicated urinary tract infection (cUTI) (51) and
complicated intra-abdominal infection (cIAI) (52) at a dose
of 1.5 g (ratio of 1.0 ceftolozane to 0.5 tazobactam) every
8 h, with double dosage (3 g; ratio of 2.0 ceftolozane to
1.0 tazobactam) in the phase III study ASPECT-NP for
the treatment of NP (53). C/T is active in several multi-
drug resistant (MDR) and extensively drug-resistant (XDR)
Enterobacteriales strains, including ESBL-producting strains and
P. aeruginosa. (54).
Regarding ESBL strains, C/T has differences depending on
the pathogen concerned. C/T, in a study published by Tato
et al. (55), seems to have higher activity against ESBL-producing
E. coli than Klebsiella spp. Moreover, among ESBL pathogens,
Castanheira et al. (56) have found that C/T retains a lower activity
in blaSHV isolates (61.1%) than blaCTX−M strains (91.2%). All
together, these data show that C/T is a major component of a
carbapenem-sparing strategy, at least in the empiric setting, even
if more evidence is needed to confirm the exact role as a targeted
treatment of ESBL infections (57).
An increased risk of hospital mortality has been linked
to inadequate initial antibiotic treatment for Pseudomonas
aeruginosa BSI (58). From a microbiological perspective, 88
percent (n = 615) of isolates were susceptible to C/T in a
major multi-center study carried out between 2012 and 2015
for meropenem-non-susceptible P. aeruginosa isolates in 32 US
medically-based centers (59).
For contrast, additional single-center surveillance studies
have shown a 60–94 percent C/T susceptibility of different
P. aeruginosa isolate populations (60–62).
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From a clinical point of view, Bassetti et al. (63) described
one of the largest clinical trials using C/T in a multicenter
cohort of 101 patients with documented P. aeruginosa infection.
Sepsis and septic shock were present at diagnosis in 26.7 and
11.9% of patients, respectively, and concomitant P. aeruginosa
bacteraemia was ruled out in only 15.8% of subjects (63).
The only independent predictor of clinical failure was sepsis
(odds ratio [OR] = 3.02, 95% confidence interval [CI]: 1.01–9.2;
P = 0.05) for patients with clinical success in comparisons to
those suffering a clinical failure with multivariate analyses (odds
ratio [OR]= 3.02, 95 per cent CI: [CI]: 1.01–9.2; P = 0.05) (63).
All together, these data show that C/T may be a
valuable option to prevent nephrotoxicity with colistin-
or aminoglycoside-sparing regimens including the risk
of subtherapeutic dosages associated with reduced renal
clearances (64, 65).
CEFTABUSE register (65) results showed a non-significant
trend toward more favorable 14-day clinical cure rates in
C/T patients than aminoglycoside or colistin (81.3 vs. 56.3%;
P = 0.11%). A similar pattern was found for crude deaths of
30 days (18.8 vs. 28.1%; P = 0.73) and acute kidney injury
prevalence (0.0 vs. 25.0%; and P = 0.04), favors C/T vs. colistin
or aminoglycoside.
Similarly, a retrospective multicenter observational
cohort study [644] also found that C/T administration was
independently associated with clinical cure (adjusted OR: 2.63;
95% CI: 1.31–5.30) and protected against AKI (adjusted OR:
0.08; 95% CI: 0.03–0.22) without any difference in in-hospital
mortality. In addition, a systematic Maraolo et al. (62) study
concluded that the therapy C/T could be useful even outside
of an accepted setting of indication for difficult-to-treat P.
aeruginosa infections: BSI is the third commonly indicated
off-label (23/130; 17.7%).
Ceftazidime/Avibactam
C/A is an intravenous combination of a third-generation
cephalosporin with the non-β-lactam/β-lactamase inhibitor
avibactam (66), with activity against ESBL-producing bacteria,
P. aeruginosa and KPC or OXA-48 carbapenemase producing
bacteria. C/A has been approved in cIAI (67), cUTI (68),
and NP (69) therapy as well as infection by microorganisms
resistant to ceftazidime, according to a specific trial (RECLAIM,
RECAPTURE, REPROVE, and REPRISE study, respectively)
and, given the comparator mainly based on carbapenem drug
administration, it is also a major component of a carbapenem-
sparing strategy. Moreover, real-life data did show clinical
efficacy in patients with KPC and OXA-48 carbapenemases.
In a prospective study, Sousa et al. (70) described a cohort
of 55 patients, 54% of whom presented with severe septic
shock or sepsis; moreover, 54 of the 57 isolates were OXA-48-
producingK. pneumoniae, 46% (26/55) of patients had confirmed
bacteraemia, and C/A was mainly given as monotherapy (81%)
with a mean duration of 13 days; The 14-day mortality rate
was 14% (70). In systematic reviews and meta-analysis with
infections by carbapenem-resistant bacteria, Fiore et al. (71)
did not observe any difference in the mortality rates between
C/A monotherapy or combination therapy (N = 503 patients;
direct evidence OR: 0.96; 95% CI: 0.65–1.41), with similar
findings in the unregistered systematic review by Onorato
et al. (72).
A retrospective longitudinal study of 138 patients with KPC-
Kp bacteraemia, in which a significantly lower mortality was
observed in any patient with C/A than other drugs (36.5 vs.
55.8%, P = 0.05), and in which this was the only factor that
was substantially correlated with survival, was addressed by
Tumbarello et al. (73). In this complex analysis, the authors
identified septic shock, neutropenia, Charlson Comorbidity
Index ≥3, and recent mechanical ventilation as independent
predictors of mortality, whereas C/A was the sole independent
predictor of survival (73). In addition, Shields confirmed higher
rates of clinical success (P = 0.006) and survival (P = 0.01)
for C/A compared to other regimens and observed higher
renal safety compared to aminoglycoside and colistin-containing
regimens (P= 0.002) (74).
All together, data from official trials and real-life experiences
showed that C/A is representing a major component in
carbapenem-sparing strategies, including patients infected by
KPC or OXA-48 carbapenemases producing bacteria in addition
to P. aeruginosa and ESBL-producing bacteria (75).
Cefiderocol
Cefiderocol is an innovative siderophore cephalosporin that
was produced to target carbapenem-resistant pathogens,
including fermenting and non-fermenting (i.e., P. aeruginosa
and Acinetobacter baumannii) GNB (76, 77). Among such
pathogens is also included Stenotrophomonas maltophilia,
which is intrinsically resistant to carbapenems (76, 78). In
the CREDIBLE CR, cefiderocol was studied in a randomized,
open-label, prospective, phase III clinical study in individuals
with carbapenem-resistant gram-negative bacteria infections,
regardless of species or infection site source and including sepsis
and BSIs (ClinicalTrials.gov registration: NCT02714595)
(79, 80). The clinical cure between cefiderocol and the
comparator, defined as best available therapy (BAT), was
similar for NP (50 vs. 53%) and BSI (43 vs. 43%). Besides,
in complicated UTIs, cefiderocol was not inferior to the
BAT group in microbiological eradication (53 vs. 20%)
(80). In the cefiderocol group, more numerical deaths
occurred, especially in the Acinetobacter spp subset, a
finding which was not unequivocally explained. These results
endorse cefiderocol as an alternative for treating patients
with limited treatment options of carbapenem-resistant
infections (80).
Wunderink et al. (81) recently published an APEKS-NP
randomized double-blind, phase III, non-inferiority analysis in
which 148 subjects and 152 subjects were allocated, respectively,
for cefiderocol and meropenem. The authors suggested that
cefiderocol was non-inferior in patients with Gram-negative NP
equal to high dose extended-infusion meropenem and similar
for all cases-mortality on Day 14 (12.4 vs. 11.6%) (81). The
findings indicate that cefiderocol is a promising solution for
treating NP, including those caused by MDR gram-negative
organisms (81).
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FIGURE 1 | Present and future perspectives within novel cephalosporins compounds.
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TABLE 1 | Advantages of monotherapy and combination antimicrobial therapy.
PROs of Monotherapy PROs of Combination Therapy
Low antibiotic pressure Avoid resistance development in
difficult-to-treat infections
Low risk of toxicities Active on different mechanism
Improve de-escalation approach In MDR infections to ensure sensitivity
Improve antibiotic stewardship bundle Accelerate pathogen clearance high
bacterial loads
Reduce the risk of antibiotic
antagonism
Improve synergy between molecules
Improve diagnosis Decrease the risk of inappropriate
empiric antibiotic therapy
Hsueh et al. (82) measured in vitro cefiderocol, C/T, and C/A
microbiological profile for P. aeruginosa and S. maltophilia and
A.baumannii isolates in the bloodstream. In comparison with the
C/T and C/A, Cefiderocol demonstrated much greater in vitro
activity with MICs ≤ 4 mg/L for P. aeruginosa isolates resistant
to colistin or imipenem (82).
Presently, in order to improve therapeutic effectiveness in
serious CRE infections, high levels and combining methods
which may have a new inhibitor β-lactam/β-lactamase are
likely to be considered (77, 78, 83). Cefiderocol has been
added to these therapeutic options, increasing the antimicrobial
spectrum to A. baumannii and S.maltophilia, which in the
last decade have been frequently omitted from the new
molecules, theoretically allowing for enhanced individualization
based on molecular resistance phenotypes, disease severity,
susceptibility profiles, and patient characteristics in antimicrobial
strategies (77, 78, 83, 84).
Besides, cefiderocol, from a pharmacokinetic point of view,
is unique for its dosing regimen to include patients with an
augmented renal clearance which is the primary cause for
underdosing in very sick patients for beta-lactams.
DISCUSSION
The creation of three fifth-generation cephalosporins has made a
major evolution in the last decade (i.e., ceftobiprole, ceftaroline,
and ceftolozane), along with the development of cefiderocol,
with its new “trojan horse” active transport mechanism for
entering multi-drug resistant bacteria, as well as through novel
therapeutic binomials (C/T and C/A) (5, 11, 44, 79). Data on
novel cephalosporins may also be available, in addition to the
official registration trials, in patients with bloodstream infections
and severe infections as well as in infections by MDR bacteria
including carbapenemases-producing bacteria from real-life
settings. In addition, the future of antimicrobial stewardship
in septic and bacteremic patients can be assessed through a
multilevel evaluation from the microbiological, pharmacological,
clinical, and financial perspectives (5, 12, 77, 78). Although the
literature is clear on specific variability in gram-negative and
gram-positive strains from various countries and cohorts, as
well as different rates of carbapenem resistance, the in vitro
susceptibilities of the novel cephalosporins are generally very
promising. (5, 12, 77, 78). This variability makes it crucial to
know their global and local epidemiologies, particularly in MDR
gram-negatives with limited treatment options. Furthermore,
there is a critical need for more pharmacological data to
assess the best dosage and administration modalities in critically
ill patients in order to avoid subtherapeutic levels of the
drug (5, 12, 77, 78).
Theoretically, such new compounds allow a sparing approach
in different antimicrobial classes, such as carbapenems,
aminoglycosides, colistin, and also vancomycin for ceftaroline
and ceftobiprole (12, 65, 77, 78).We are presented withmolecules
with an increasingly strong pathogen-specific identity, such as
C/T for MDR/XDR P. aeruginosa and cefiderocol for difficult-to-
treat CR strains, and we face a great change in the management
of MRSA and endovascular bacteremia due to the evolving
clinical data on ceftaroline and ceftobiprole (5, 11, 44, 79).
Time seems to be on the side of these novel cephalosporins,
making them useful in several severe infections (Figure 1).
These molecules can also be used in therapeutic combinations,
under particular circumstances. The primary rationale for using
two distinct classes of antibiotics with activity against a single
pathogen is, on the one hand, to potentiate pathogen clearance
and, on the other, to assure the pathogen’s susceptibility to the
empiric therapy (85, 86). Conversely, monotherapy reduces the
risk of antibiotic pressure, the rate of new infections, antibiotic
antagonism, toxicity, and costs, though it may not cover
MDR pathogens (Table 1) (85, 86). Combination antibiotic
treatment was recommended in international guidelines for
primary management of septic shock to provide appropriate
empirical antibiotic coverage in a scenario with high risk of
MDR pathogens (87). However, several other studies found no
superiority of combination treatment, and some analyses showed
an increased rate of side effects in patients receiving combination
therapy (88–90). The desired approach to sepsis and serious
infections would be presented to patients in the future based
on their clinical condition, host characteristics, susceptibility
profiles, and local epidemiology, which would fill the gaps in the
use of new cephalosporins that currently exist. Finally, literature
data emphasize the small spread of every study and also stress
the importance of local monitoring. When determining early
use of these agents in severely ill patients, careful consideration
should be given to local susceptibility patterns.
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